IPO
Nineteen companies went public during the year, with two offerings nabbing proceeds of more than $1 billion and two more above $500 million.Â
Bluejay Diagnostics Prices $21.6M IPO
The firm anticipates using the net proceeds from the offering for general corporate purposes and to support the development and marketing of its IL-6 Sepsis Triage test.
German MDx Firm Mainz Biomed Raises $10M in IPO, Begins Trading on Nasdaq
The company, which has been developing a colorectal cancer diagnostic called ColoAlert, priced its IPO last week, offering 2 million shares at $5 per share.
MDxHealth Prices IPO of American Depositary Shares
The diagnostics company is offering 3.75 million ADSs at $12 per share and is hoping to raise gross proceeds of $45 million.
Lucid Diagnostics Prices $70M IPO, Starts Trading on Nasdaq
Lucid markets an esophageal DNA test and cell collection device for the detection of gastroesophageal reflux disease, and esophageal precancer and cancer.
Sep 2, 2021
Cue Health Files for IPO for up to $100M
Jul 19, 2021
Sophia Genetics Increases IPO Target to $221M
Jul 14, 2021
Sera Prognostics Goes Public With $75M IPO
Jun 30, 2021
Apr 28, 2021
Mar 12, 2021
Prometheus Biosciences Prices Upsized $190M IPO
Jan 28, 2021
Ortho Clinical Diagnostics Prices $1.29B IPO
Jan 19, 2021